It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Zynerba Pharmaceuticals Inc (ZYNE) USD0.001

Sell:$4.60 Buy:$4.80 Change: $0.21 (4.68%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Sell:$4.60
Buy:$4.80
Change: $0.21 (4.68%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Sell:$4.60
Buy:$4.80
Change: $0.21 (4.68%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Contact details

Address:
80 W. Lancaster Avenue, Suite 300
DEVON
19333
United States
Telephone:
+1 (484) 5817505
Website:
zynerba.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZYNE
ISIN:
US98986X1090
Market cap:
$183.98 million
Shares in issue:
41.25 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Armando Anido
    Chairman of the Board, Chief Executive Officer
  • Terri Sebree
    President
  • James Fickenscher
    Chief Financial Officer, Vice President - Corporate Development
  • Suzanne Hanlon
    Vice President, General Counsel, Secretary
  • Brian Rosenberger
    Vice President - Commercial and Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.